Pre Diagnostics was founded in 2013 by Håkon Sæterøy and Erik Christensen. The company acquired the rights to develop and commercialize a novel patented technology that was first discovered by Tormod Fladby, Lisbeth Johansen and Kaj Blenow in 2009 during their tenure at Akershus University Hospital. Based at ShareLab in the Oslo Science Park, development work is now also performed “in house” by Pre Diagnostics’ team at ShareLab. The company runs a lean operation and the strategy remains to leverage a network of strong collaboration partners.
Today Pre Diagnostics is based in modern facilities with a cutting edge laboratory infrastructure at Parallel in Oslo, Norway. The company today focuses on developing biomarkers for neurodegenerative diseases. The novel biomarkers under development are intended to be applied both for pharma clinical research, patient monitoring/screening as well as diagnostics. The company is in active dialogue with several pharmaceutical companies to commercialize the biomarkers built on PreDx’s technology platform to the benefit of patients with neurodegenerative diseases. This first biomarkers to be launched are within Alzheimer’s and Parkinsons disease.